All In Biotech

Drug Trial Radar · NCT01124565

Safety Study of Two Repeat Doses of RT001 for the Treatment of Moderate to Severe Lateral Canthal Lines in Adults

A Phase 2, Open-Label, Repeat Dose, Multi-Center Study to Evaluate the Safety of RT001 Topical Gel for the Treatment of Moderate to Severe Lateral Canthal Lines in Adults

Last checked: Nov 19, 2026Latest source record: Jan 17, 2014 (this record)Source: ClinicalTrials.govMethods & limitations

Completed

Status

Completed

Enrollment

40

Actual

Start

May 2010

Primary completion

Jul 2010

Study completion Jul 2010

Sponsor

Lead sponsor
Revance Therapeutics, Inc.Industry
Sponsor type
Industry
First posted
May 17, 2010

More drug trials from this sponsor

Design

Study type
Interventional
Phase
Phase 2
Allocation
Not applicable (single group)
Model
Single group
Masking
None
Primary purpose
Treatment
Who can join
All sexes, from 18 years, up to 65 years
Healthy volunteers
Yes

Summary

As written by the sponsor on the registry.

This study's objective is to evaluate if RT001 is safe and well-tolerated following two (2) sequential applications.

Conditions

  • Lateral Canthal Lines
  • Crow's Feet
  • Facial Wrinkles

Interventions

  • RT001Drug

    RT001 (Botulinum Toxin Type A Topical Gel, Dose A) at Baseline (Day 0) and Week 4 to the lateral canthal areas

Primary outcomes

What the sponsor says the trial is designed to measure.

  1. Assessment of treatment-emergent adverse events based on safety assessments.Time frame: 4 weeks and 8 weeks

Locations

3 sites in 1 country. Site status is shown where the registry gives one.

  • Total Skin & Beauty Dermatology Center, PC

    Birmingham, Alabama

  • Therapeutics Clinical Research

    San Diego, California

  • Skin Specialists, PC

    Omaha, Nebraska

Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.

For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.